CoreWeave, Inc. (Nasdaq: CRWV) ("CoreWeave") announced today the pricing of its private offering of $3.5 billion aggregate ...
The Notes are senior, unsecured obligations of the Company and bear interest at 1.75% per year. Interest is payable semi-annually in arrears on April 15 and October 15 of each year, beginning on ...
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the ...
Scorpio Tankers Inc. (NYSE: STNG) (the “Company”) announced today that it priced a private offering (the “Offering”) of $325 million aggregate principal amount of 1.75% convertible senior notes due ...
CoreWeave (CRWV) stock jumped 12.65% to $103.64 after the company priced a $3.5 billion convertible notes offering to fund AI ...
NEW YORK--(BUSINESS WIRE)--WisdomTree, Inc. (NYSE: WT) (“WisdomTree”), a global financial innovator, today announced its intention to offer, subject to market conditions and other factors, $525.0 ...
Scorpio Tankers (STNG) announced pricing of a private offering of $325M of 1.75% convertible senior notes due in 2031. This amount is an increase from the initially planned $300M. The company also ...
LOS ANGELES, CA / ACCESS Newswire / April 8, 2026 / Clean Vision Corporation (OCTQB:CLNV) ("Clean Vision" or the "Company"), an emerging leader in innovative plastic conversion and clean fuel developm ...
Hosted on MSN
WisdomTree prices ~$604M convertible notes due 2031
WisdomTree (WT) priced a $603.75M convertible notes offering due 2031, including the full exercise of an additional $78.75M option by the initial purchasers. The notes will bear interest at 4.50% per ...
The stocks notably clocked 20 to 50 percent gains week-on-week and were dominated by companies riding the AI wave.
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization ...
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results